Alice Sacco

Dr. Alice Sacco

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in JACC
Verified
Journal Article
Open access
NMNuccia Morici
Nuccia Morici
ASAlice Sacco
Alice Sacco
SFSimone Frea
Simone Frea
MRMatteo Rota
Matteo Rota
LVLuca Villanova
Luca Villanova
FPFederico Pappalardo
Federico Pappalardo
The impact of intra-aortic balloon pump (IABP) on survival and successful bridging to heart replacement therapies (HRT) in patients with heart failure-cardiogenic shock (HF-CS) remains unclear. The purpose of this study was to evaluate the effect of early IABP use vs standard care on 60-day survival or successful bridging to HRT. In the multicenter, prospective Altshock-2 (Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock), patients with Society for Cardiovascular Angiography and Interventions stage B, C, or D HF-CS and suitable for HRT were randomized to receive early IABP plus standard care (IABP group) or standard care (control group). The primary endpoint was survival or successful bridge to HRT at 60 days. Secondary endpoints included overall survival, maximum inotropic score, and maximum sequential organ failure assessment score. In total, 53 patients were randomized to IABP and 48 to standard care. Patients were Society for Cardiovascular Angiography and Interventions stage B (28%, n = 28), C (57%, n = 56), and D (15%, n = 16). At the prespecified interim analysis, the trial was stopped because of futility. The primary endpoint was reached in 43 patients (81%) in the IABP group and 36 patients (75%) in the control group (HR: 0.72; 95% CI: 0.31-1.68; P = 0.45). A total of 37 patients (37%) underwent HRT within the 60-day follow-up. Four patients were escalated in the study group (7.5%) vs 2 in the control group (4.2%). Additionally, 6 patients (13%) initially assigned to standard care crossed over to IABP. Complications were comparable between groups. Routine early IABP plus standard care, compared with standard care, did not significantly improve survival or successful bridging to HRT in patients with HF-CS. (Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock [Altshock-2]; NCT04369573).

15 November 2022 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
NMNuccia Morici
Nuccia Morici
SFSimone Frea
Simone Frea
MBMaurizio Bertaina
Maurizio Bertaina
ASAlice Sacco
Alice Sacco
ECElena Corrada
Elena Corrada
FPFederico Pappalardo
Federico Pappalardo
Background: Cardiogenic shock (CS) includes several phenotypes with heterogenous hemodynamic features. Timely prognostication is warranted to identify patients requiring treatment escalation. We explored the association of the updated Society for Cardiovascular Angiography and Interventions (SCAI) stages classification with in‐hospital mortality using a prospective national registry.Methods: Between March 2020 and February 2022 the Altshock‐2 Registry has included 237 patients with CS of all etiologies at 11 Italian Centers. Patients were classified according to their admission SCAI stage (assigned prospectively and independently updated according to the recently released version). In‐hospital mortality was evaluated for association with both admission and 24‐h SCAI stages.Results: The overall in‐hospital mortality was 38%. Of the 237 patients included and staged according to the updated SCAI classification, 20 (8%) had SCAI shock stage B, 131 (55%) SCAI stage C, 61 (26%) SCAI stage D and 25 (11%) SCAI stage E. In‐hospital mortality stratified according to the SCAI classification at 24 h was 18% for patients in SCAI stage B, 27% for SCAI stage C, 63% for SCAI stage D and 100% for SCAI stage E. Both the revised SCAI stages on admission and at 24 h were associated with in‐hospital mortality, but the classification potential slightly increased at 24‐h. After adjusting for age, sex, lactate level, eGFR, CVP, inotropic score and mechanical circulatory support [MCS], SCAI classification at 24 h was an independent predictor of in‐hospital mortality.Conclusions: In the Altshock‐2 registry the utility of SCAI shock stages to identify risk of in‐hospital mortality increased at 24 h after admission. Escalation of treatment (either pharmacological or with MCS) should be tailored to achieve prompt clinical improvement within the first 24 h after admission. Registration: http://www.clinicaltrials.gov; Unique identifier: NCT04295252.

16 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMALESSANDRO MALOBERTI
ALESSANDRO MALOBERTI
MBMarco Biolcati
Marco Biolcati
GRGiacomo Ruzzenenti
Giacomo Ruzzenenti
VGValentina Giani
Valentina Giani
FLFilippo Leidi
Filippo Leidi
CGCristina Giannattasio
Cristina Giannattasio
Uric acid (UA) is the final product of the catabolism of endogenous and exogenous purine nucleotides. While its association with articular gout and kidney disease has been known for a long time, new data have demonstrated that UA is also related to cardiovascular (CV) diseases. UA has been identified as a significant determinant of many different outcomes, such as all-cause and CV mortality, and also of CV events (mainly Acute Coronary Syndromes (ACS) and even strokes). Furthermore, UA has been related to the development of Heart Failure, and to a higher mortality in decompensated patients, as well as to the onset of atrial fibrillation. After a brief introduction on the general role of UA in CV disorders, this review will be focused on UA’s relationship with CV outcomes, as well as on the specific features of patients with ACS and Chronic Coronary Syndrome. Finally, two issues which remain open will be discussed: the first is about the identification of a CV UA cut-off value, while the second concerns the possibility that the pharmacological reduction of UA is able to lower the incidence of CV events.

1 July 2022 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
NMNuccia Morici
Nuccia Morici
CMClaudia Marini
Claudia Marini
ASAlice Sacco
Alice Sacco
GTGuido Tavazzi
Guido Tavazzi
FSFrancesco Saia
Francesco Saia
FPFederico Pappalardo
Federico Pappalardo

26 April 2022 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
MBMaurizio Bertaina
Maurizio Bertaina
AGAlessandro Galluzzo
Alessandro Galluzzo
NMNuccia Morici
Nuccia Morici
ASAlice Sacco
Alice Sacco
FOFabrizio Oliva
Fabrizio Oliva
Mario IannacconeMario Iannaccone
Mario Iannaccone
Cardiogenic shock represents one of the most dramatic scenarios to deal with in intensive cardiology care and is burdened by substantial short-term mortality. An integrated approach, including timely diagnosis and phenotyping, along with a well-established shock team and management protocol, may improve survival. The use of the Swan-Ganz catheter could play a pivotal role in various phases of cardiogenic shock management, encompassing diagnosis and haemodynamic characterisation to treatment selection, titration and weaning. Moreover, it is essential in the evaluation of patients who might be candidates for long-term heart-replacement strategies. This review provides a historical background on the use of the Swan-Ganz catheter in the intensive care unit and an analysis of the available evidence in terms of potential prognostic implications in this setting.

27 December 2021 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
VDValentina Ditali
Valentina Ditali
LGLaura Garatti
Laura Garatti
NMNuccia Morici
Nuccia Morici
LVLuca Villanova
Luca Villanova
CCClaudia Colombo
Claudia Colombo
ASAlice Sacco
Alice Sacco
Tachycardia and rapid tachyarrhythmias are common in acute clinical settings and may hasten the deterioration of haemodynamics in patients with acute decompensated heart failure (ADHF), treated with inotropes. The concomitant use of a short-acting β1-selective beta-blocker, such as landiolol, could rapidly and safely restore an adequate heart rate without any negative inotropic effect. We present a case series of five patients with left ventricular dysfunction, admitted to our Intensive Cardiac Care Unit with ADHF deteriorated to cardiogenic shock, treated with a combination of landiolol and inotropes. Landiolol was effective in terms of rate control and haemodynamics optimization, enabling de-escalation of catecholamine dosing in all patients. The infusion was always well tolerated without hypotension. In conclusion, a continuous infusion of a low dose of landiolol (3–16 mcg/kg/min) to manage tachycardia and ventricular or supraventricular tachyarrhythmias in haemodynamically unstable patients may be considered.